Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Muvalaplin · LY-3473329

Small molecule · developed by ELI LILLY &

Phase 3 Most advanced trial

LLY Developer

What is Muvalaplin?

Muvalaplin (LY3473329) is a small-molecule therapeutic studied in elevated lipoprotein(a) and atherosclerotic cardiovascular disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: LY-3473329
Drug type: Small molecule
Therapy area: Cardiovascular
Developer: ELI LILLY & (LLY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: HSU2KY4EFK

Conditions studied

Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Follow LLY, the company behind Muvalaplin

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z